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Purpose: ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to 
sensitise to chemotherapy and radiotherapy preclinically.  Limited data have been published 
about the effect of these drugs on the tumor microenvironment.  
 
Experimental Design: We used an immunocompetent mouse model of HPV-driven 
malignancies to investigate the ATR inhibitor AZD6738 in combination with fractionated 
radiation (RT). Gene expression analysis and flow cytometry were performed post-therapy. 
 
Results: Significant radiosensitization to RT by ATRi was observed alongside a marked 
increase in immune cell infiltration. We identified increased numbers of CD3+ and NK cells 
but most of this infiltrate was composed of myeloid cells. ATRi plus radiation produced a 
gene expression signature matching a type I/II interferon response with upregulation of 
genes playing a role in nucleic acid sensing. Increased MHC I levels were observed on 
tumor cells, with transcript-level data indicating increased antigen processing and 
presentation within the tumor.  Significant modulation of cytokine gene expression 
(particularly CCL2, CCL5 and CXCL10) was found in vivo, with in vitro data indicating CCL3, 
CCL5 and CXCL10 are produced from tumor cells after ATRi + RT.  
 
Conclusions: We show that DNA damage by ATRi and RT leads to an interferon response 
through activation of nucleic acid sensing pathways. This triggers increased antigen 
presentation and innate immune cell infiltration. Further understanding of the effect of this 
combination on the immune response may allow modulation of these effects to maximise 
tumor control through anti-tumor immunity. 
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Statement of Translational Relevance 
 
AZD6738 is currently under investigation in clinical trials in combination with radiotherapy 
(NCT02223923). Substantial preclinical data exist on the radiation potentiating effects of 
drugs inhibiting components of the DNA damage response. Given the increased 
understanding of the pivotal role of the immune system in cancer control, it is critical to 
understand the effect radiosensitizer compounds have on the tumor microenvironment, 
specifically their impact on the immune system and its responses. AZD6738 boosts the 
immunogenic effect of radiation, enhancing tumor-derived cytokine production, antigen 
presentation and infiltration of myeloid lineage immune populations. Both inflammatory and 
immunosuppressive cells are increased after the combination treatment. The modulation of 
these responses to maximise anti-tumor immunity and effect on adaptive responses will be 








In recent years, we have begun to understand that the effects of anti-cancer therapies 
cannot be considered purely from the narrow perspective of their ability to kill cancer cells 
effectively. Instead, their effects on the tumor microenvironment are increasingly recognised 
as playing a major role in the success or failure of treatment.  An appreciation of the 
importance of the immune system to cancer surveillance, development and response to 
treatment has highlighted the effect that radiation has on the microenvironment, and has 
served as a driver of research into combinations of radiation and immune-targeted therapies 
(1).  At the same time, increasing recognition of the effect of the vasculature and stroma on 
tumor control and normal tissue side-effects of radiotherapy has highlighted potential new 
targets for intervention (2). 
 
Radiation has positive and negative effects on the tumor microenvironment.  Radiation 
increases antigen presentation and T-cell priming, and can stimulate systemic (abscopal) 
anti-tumor responses, particularly when co-administered with immune checkpoint blockade 
(3).  On the other hand, it can stimulate suppressive cells such as myeloid-derived 
suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), which have been 
associated with tumor angiogenesis and invasion (4).  Links between the DNA damage 
response (DDR) and both autoimmunity and anti-cancer immunity are increasingly being 
described.  The STING pathway, activated by cytosolic DNA, stimulates type I interferon 
production, leading to immune responses (5).  Defective DDR, S-phase DNA damage and 
micronucleus formation can trigger interferon production and alter the expression/function of 
cell surface immunomodulatory molecules (6-8).  Targeted anti-cancer therapies can also 
exert diverse effects on the immune microenvironment (9).  Few data have been reported on 
the microenvironmental effects of radiation in combination with radiosensitizing agents, such 
as DDR inhibitors.  Understanding these effects may provide opportunities for further 
therapeutic benefit, especially in terms of immunotherapy strategies. 
 
Here, we show that the ATR inhibitor, AZD6738, alone and in combination with a clinically 
relevant fractionation schedule of radiotherapy modulates the immune tumor 
microenvironment.  To our knowledge, this is the first comprehensive profiling of the immune 
tumor microenvironment in the context of targeted radiosensitization. 
  
Dillon et al ATRi + RT Create an Inflammatory Tumor Microenvironment 
 
5 
Materials and Methods 
Animals and cell lines 
All experiments were approved by the Institutional Review Board and complied with National 
Cancer Research Institute guidelines (10).  TC-1 cells – a modified mouse lung epithelial cell 
line transformed with HPV-16 E6 and E7 and oncogenic HRAS -  were a kind gift from Prof. 
Tzyy-Choou Wu, Johns Hopkins University, Baltimore, USA (11) and Prof. Eric Deutsch, 
Institut Gustave Roussy, Villejuif, France.  Two million cells were injected subcutaneously 
into the right flank of female C57Bl/6 mice; treatments were started 7-8 days later, at which 
point tumors were 50–100 mm3.  The experimental endpoint for growth delay experiments 
was a tumor diameter of 15 mm or greater.  
Drugs 
AZD6738 was provided by AstraZeneca and was dissolved in 10% DMSO, 40% propylene 
glycol, 50% water and administered by oral gavage, 2 hours before irradiation.  For hypoxia 
studies, pimonidazole (Hypoxyprobe, HPI, Burlington, USA) 60 mg/kg was injected 
intraperitoneally 1 hour prior to tissue collection. 
Irradiation 
Animals were irradiated under anaesthesia with hypnorm (Fentanyl/fluanisone, Vetapharma, 
Leeds, UK) and Midazolam (Roche) given intraperitoneally.  Irradiation was performed using 
an AGO 250 kV X-ray machine at a dose rate of 1.62 Gy/min (AGO, Reading, UK).  Animals 
were irradiated in the prone position positioned under lead shielding with a 16 mm diameter 
aperture aligned over the tumor.  Radiation dose was measured using a Farmer chamber 
and Unidos-E dosemeter (both PTW, Freiburg, Germany). 
Immunophenotyping 
Viability dye: eBioscience fixable viability dye eFluor 780 (65-0865-14). Antibodies: 
conjugated antibodies were obtained from BioLegend (San Diego, USA) unless otherwise 
stated. Antibodies used are shown in supplementary table 1. Tumors were harvested and 
kept on ice, then blotted dry and weighed before mechanical dissociation with scissors and 
enzymatic digestion for 30 minutes at 37 ºC with (per sample) 40 L 0.25% trypsin, 20 μL 
collagenase (Sigma C1639 25 mg/mL in PBS), 2 μL dispase (200 mg/mL) and 10 μL DNAse 
(20 mg/mL), before passing through a 70 μm cell strainer and rinsing with RPMI 
supplemented with 10% FCS and 5 mM EDTA.  Samples were resuspended in PBS with 5 
% FCS, blocked with anti-CD16/32 antibody (BioLegend 101319) for 10 mins on ice then 
stained immediately on ice in a staining volume of 40 μL, diluting antibodies at the dilutions 
given in supplementary table 1 in PBS with 5% FCS for 30 minutes before washing twice.  
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For intracellular epitopes, samples were fixed and permeabilized after staining for 
extracellular epitopes, using the FoxP3/Transcription factor Fixation/Permeabilization kit 
(eBioscience 00-5521-00, Thermo Fisher, Waltham, USA) in accordance with the 
manufacturer’s protocol. Subsequent staining was performed using the permeabilization 
buffer from this kit.  After fixation, samples were washed twice and fixed using 1% 
formaldehyde in PBS before acquisition on a BD LSRII flow cytometer (BD Biosciences, 
Oxford, UK).  Photomultiplier tube voltages were set using fully stained samples, and 
compensation was performed using single-stained UltraComp eBeads (eBioscience). Gating 
was performed using ‘fluorescence minus one’ controls and a limited number of isotype 
controls were used (supplementary table 1). The sample was divided equally into staining 
panels and each sample was acquired entirely.  Data were analysed using FlowJo software 
(FlowJo, Ashland, USA); counts were normalised to tumor weight and corrected for the 
number of panels into which the sample was divided. 
RNA analysis 
Tumor samples were harvested from animals and stored in RNALater (AM7020, Thermo 
Fisher) at -20 ºC prior to RNA extraction.  Samples were processed by homogenization 
using a Precellys24 homogenizer (Bertin Technologies, Montigny, France) and RNA 
extraction performed using RNEasy kit (74104, Qiagen, Germantown, USA) as per 
manufacturer’s protocol.  Paired CD45-negative and CD45-positive samples were generated 
by disaggregation and staining using CD45 30-F11 as for immunophenotyping. Sorting was 
performed using a FACS Aria III. Samples were kept on ice at all times other than enzymatic 
digestion, sort was performed under chilled conditions. RNA extraction on sorted cell pellets 
was by RNEasy kit. Extracted RNA was quantified using a NanoDrop spectrophotometer 
(Thermo Fisher) and quality assessed on a BioAnalyzer 2100 (Agilent, Santa Clara, USA).  
Samples were stored at -80 ºC before further analysis.  100 ng RNA was used for the 
analysis using the nCounter PanCancer Immune Profiling Panel (XT-CSO-MIP1-12, 
NanoString Technologies, Seattle, USA).  Data analysis was performed using the nSolver 
advanced analysis software (NanoString Technologies). PTPRC (CD45) transcript counts in 
sorted samples post-normalisation ranged from 20-129 in CD45-negative and 9234-11298 
for CD45-positive samples. As a precaution, minor CD45-positive contamination of treated 
CD45-negative samples (0.9-0.3%) was corrected for by subtraction of the corresponding % 
of transcripts from paired CD45-positive samples calculated based on PTPRC transcript 
counts. This was to avoid false positive changes associated with isolated high transcript 
genes. Differential expression was compared between two conditions, p-values were 
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adjusted using the Benjamini-Yekutieli false discovery rate; genes with adjusted p-values < 
0.05 are displayed.  Functional annotations were based on gene ontology terms. 
Immunohistochemistry 
Immunohistochemistry was performed at the Breast Cancer Now core histopathology facility, 
using the following primary antibodies.  Dako Flex Envision (K8002) was used as the 
secondary reagent: pS345Chk1, Thermo Fisher PA5-34625; CD3, Dianova clone SZ31, DIA-
310; CD45R, Abcam ab64100; Pimonidazole, hypoxyprobe, MAb1; Carbonic Anhydrase IX: 
Abcam ab15086; Smooth muscle actin, Dako clone 1A4, M0851. 
Western blot 
Snap frozen tumour samples were lysed in RIPA buffer using a Precellys 24 homogenizer 
(Bertin Technologies). All lysates were quantified by BCA assay (Thermo Fisher) prior to 
SDS-PAGE and western blotting. The following antibodies were used: GAPDH 14C10, 
MDA5 D74E4 and cGAS D3O8O (Cell Signaling). Secondary was IRDye 800CW Goat anti-
Rabbit IgG H + L and imaged using a LI-COR Odyssey CLx  (LI-COR Biosciences). 
Statistical analyses 
Statistical analysis was performed using Prism 7 (GraphPad Software, San Diego, USA). 
For tumor growth delay, means of radiation and radiation + ATRi groups were compared 
using Student’s unpaired t-test.  Flow cytometry cell counts, mRNA count and proportions 
and fluorescence data were compared using one-way ANOVA with Tukey’s multiple 
comparisons test.  An asterisk indicates p 0.05.  Where multiple asterisks are used, ** 
indicates p  0.01, *** indicates p  0.001 and **** indicates p  0.0001. 
  




ATRi and ATRi-RT modulate the immune microenvironment 
Two participants in the dose-escalation study of AZD6738 monotherapy (12) had tumor 
volume reductions.  We noted that this was associated with an inflammatory infiltrate in one 
of the participants, and hypothesised that AZD6738 may have a modulating effect on the 
immune tumor microenvironment.  We sought to investigate how AZD6738 may modulate 
radiation induced changes to the tumor microenvironment (TME). 
 
TC-1 is an immunocompetent model of HPV-driven malignancies.  This model was chosen 
as it has previously been used for examining immune responses to radiotherapy 
combinations, and it was moderately sensitive to combination therapy, allowing sufficient 
tumor for analysis at the time point chosen. Mice bearing subcutaneous TC-1 tumors were 
treated 8 days after implantation, at which point tumors were 50 – 100 mm3.  Mice were 
dosed with vehicle or AZD6738 (75 mg/kg daily), starting 2 hours before the first dose of 
radiation, with the last dose given on day 5.  Irradiation was given daily, 2 hours after drug or 
vehicle dosing, at 2 Gy per fraction for 4 days.  ATR inhibition sensitised this model to 
radiation, with significantly greater tumor growth delay (Fig. 1A) and a significant increase in 
survival to humane endpoint (Supp. Fig. 1A). 
 
Initial profiling of the TME was carried out 5 days after irradiation on formalin-fixed tissue. 
This was focused on broad markers investigating vessel density, hypoxia, fibroblasts, CD3+ 
(T) and CD45R/B220+ (B) cells. Because hypoxia is an important determinant of 
radiosensitivity, we wanted to examine whether the radiosensitization by AZD6738 was due 
to modulation of perfusion or hypoxia. Microenvironmental markers of hypoxia 
(pimonidazole, CAIX) and fibroblasts (αSMA) did not differ significantly between treatment 
groups (Supp. Fig 2A-C).  Vessel density after 4 x 2 Gy measured by CD31 had significantly 
reduced compared with control.  When AZD6738 was added to radiation this reduction was 
reversed (Supp. Fig 2D). We did observe increased numbers of T-cells (Fig. 1B) and B cells 
(Fig. 1C) after combination treatment with radiation and AZD6738. Given these findings, 
further work focussed in detail on the effect of ATRi plus radiation (ATRi-RT) on the immune 
tumor microenvironment.  
 
 
ATRi-RT modulates multiple immune-related genes 
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NanoString-based expression profiling of TC-1 tumors was carried out to comprehensively 
profile gene expression changes 5 days after the end of radiation. This time point was 
selected initially to focus more on infiltrating immune population markers post-DNA damage. 
This revealed changes in expression in multiple categories of genes due to radiation or 
AZD6738 alone, with the addition of AZD6738 potentiating radiation-induced changes (Fig. 
2A). This was particularly pronounced in the gene ontology groups CD molecules, apoptosis, 
adaptive, antigen processing and MHC. Numbers of genes with significant differential 
expression are shown in Fig. 2B.  Strikingly, we found evidence of an interferon response, 
with large changes in expression of a number of interferon-stimulated genes (Fig. 2C (13), 
supp. fig. 3, 4). Numerically, the combination of ATRi and radiation caused the largest 
number of changes and greatest degree of change in gene expression. 
 
These gene expression changes suggest infiltration and activation of innate and adaptive 
immune cells, which was maximal after combined ATRi-RT treatment. 
 
ATRi-RT increases lymphocyte infiltration  
Flow cytometry was used to validate specific intratumoral cell population data identified by 
gene expression analysis presented in Figure 2.  A more focused analysis was also 
undertaken in the draining lymph nodes (DLN).  The general lymphoid gating strategy for 
FACS analysis is shown in supplementary Fig. 5 and 6. 
 
Greater numbers of total CD3+ cells over control were demonstrated after treatment with 
ATRi, radiation, and maximal levels were seen with combination therapy (Fig. 3A, this 
observation was maintained when analysed for the total number of cells, supp. Fig. 7). There 
were also significantly increased numbers of CD4+ FOXP3+ Tregs and NK cells.  There was a 
non-significant trend towards increase in CD8+ cells observed with combination therapy 
(Fig. 3A), with a higher proportion of CD8+ granzyme B+ as well as CD8+ Ki67+ cells 
observed with combination therapy (Fig. 3B). This correlated with transcript-level data 
observed, where Cd8a, granzyme B (Gzmb) and perforin (Prf1) were highest in the 
combination group (Fig 3C).   
 
Analysis of markers of activation and proliferation showed a significantly increased 
proportion of proliferating Tregs with the combination treatment (Fig. 3B). These results 
confirmed the transcriptional analysis which showed increased T-cell-associated and Foxp3 
transcripts in tumors (Fig. 3C).  The draining lymph nodes also contained an increased 
proportion of proliferating Ki67+ Tregs as a function of total Tregs (Fig. 3D). 
 
Dillon et al ATRi + RT Create an Inflammatory Tumor Microenvironment 
 
10 
To further define infiltrating lymphocytes, flow cytometry was performed on T-cell subsets 
with a selection of markers (Fig. 3E). While not statistically significant, a consistent trend 
was observed for increased expression of LAG3, TIM3, ICOS and CTLA4 on CD4+ effector 
cells in the ATRi-RT combination group.  No significant changes in fluorescence were found 
in Tregs or CD8+ T cells (data not shown). Similar but more statistically significant changes 
were observed at the transcript level. Havcr2 (TIM3), Tigit, Icos and Eomes were 
upregulated in ATRi-RT compared with control or either monotherapy (Supp. fig. 8A).  
Further mRNA analysis showed increased numbers of transcripts associated with a Th1 
response, including Il12rb2, Ctla4 and Stat4 (Supp. fig. 8B) between control and RT, control 
and ATRi-RT.  When transcriptional analysis was performed on sorted CD45-postive tumor-
infiltrating cells alone, there was a significant increase in Gzmb transcripts (Fig. 3F).  Taken 
together, these data suggest increased Treg proliferation as well as evidence of CD4 effector 
cell activation or exhaustion with combination treatment. 
 
ATRi-RT causes an increase in myeloid cell infiltration 
Further validation of gene expression data identified that AZD6738 and radiation induced 
substantial infiltration of myeloid innate immune cells (Fig 4A, supp. fig. 7B). The general 
myeloid gating strategy for FACS analysis is shown in supplementary Fig. 6. A significant 
increase was seen in tumor-infiltrating dendritic cells (DCs), macrophages (Mac), and a 
CD11b+Gr1+ population (Fig. 4A)(14). This increase was clear but not statistically significant 
compared to controls for both monotherapies, but highest and statistically significant for 
ATRi in combination with radiation. In absolute numbers, the cumulative infiltration of these 
three populations was approximately three times the total number of CD3+ cells in the 
combination group (Fig 3A; Fig 4A). 
 
Flow cytometry was used to determine if ATRi-RT altered specific subpopulations of DCs, 
macrophages or CD11b+Gr1+ cells. Based on CD206 staining, we did not detect any 
change in the proportions of M2-like macrophages (Fig 4B). Ly6C, a monocytic marker, 
showed that there was no clear shift in the monocytic CD11b+Gr1+ cell population with 
combination treatment vs control (Fig. 4C).  On the other hand, granulocytic marker Ly6G 
staining showed that the numbers of granulocytic CD11b+Gr1+ cells were lower (supp. fig. 
6). Two subsets of DC, classical (cDC) and plasmacytoid (pDC), were investigated because 
pDC have toll-like receptors 7 and 9, which sense RNA and DNA, respectively. We 
hypothesised that the increased DNA damage with ATR inhibition may activate these pattern 
recognition receptors. Tumor-associated pDC may increase tumor antigen presentation or 
may be tolerogenic (15).  B220 has been described as a marker for pDC in CD11c+ DC (15).  
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No difference was found in proportions of pDC and cDC, using flow cytometric analysis of 
CD11c and B220 staining, with cDC making up the majority of DC within the tumor, and 
numbers of both increasing with ATRi-RT treatment (Fig. 4D). Although ATRi-RT increases 
both the numbers of DCs and TAMs, it does not alter the DC subsets investigated, or the 
polarity of TAMs. 
 
We noted an increase in both PD-1 and PD-L1 mRNA with ATRi and ATRi-RT therapy 
(Supp. fig. 8C), which confirmed flow cytometry analysis, finding that the predominant 
increase in PD-L1 signal was from CD45+ CD3- cells, with a relatively minor contribution 
from tumor cells (Fig. 4E). Transcriptional analysis of sorted tumor-infiltrating immune cells 
and CD45-negative cells, a surrogate for tumor cells, showed a significant increase in Cd274 
(PD-L1) transcripts in both populations (Fig. 4F).  Previous data have shown that tumor-
infiltrating MDSC and macrophages are PD-L1+ (16, 17), and our observations have 
confirmed this, with increasing PD-L1-positivity after treatment with ATRi, radiation, and the 
combination (Fig. 4E). 
 
Using pan-cytokeratin as a marker for tumor cells, we observed a significant increase in 
MHC-I expression with all conditions compared with control (Fig. 4F).  Pan-cytokeratin is 
generally expressed on tumor cells, but may not be specific to these.  mRNA expression 
data confirmed the increase in H2 complex molecules on CD45-negative cells, as well as a 
number of other components involved in antigen processing and presentation on both CD45-
positive and –negative cells.  These include H2 class I on tumor cells, class II on immune 
cells, and other genes involved in the antigen presentation processes (Fig. 4H). 
ATRi and radiation drives immune cell infiltration through tumor cell-intrinsic 
cytokine release 
ATRi and radiation clearly drive immune cell infiltration, particularly of the myeloid 
compartment, in response to therapy. The process driving this infiltration was, however, not 
clear. To investigate the potential trigger for immune cell infiltrates seen after ATRi -RT, 
differential expression for cytokine and cytokine receptor mRNAs was analysed (Fig. 5A).  In 
all cases statistically significant changes were observed at the transcript level for ATRi-RT. 
The greatest changes after the combination of ATRi-RT were in Ccl5, Il1r2 (IL-1 receptor 2), 
Il2rb, Il2ra, Ccr2, Ccr7 and Cxcl9.  In addition, we performed mRNA analysis on tumor cell 
populations sorted for CD45, which confirmed the large increases seen in Ccl2, Ccl5 and 
Cxcl10 were predominantly from non-immune cells (Fig. 9B).  These data were compared 
with protein expression by cytokine array (Fig. 5C).  Clear correlation between increased 
transcript levels and increased protein expression was observed for CCL2, CCL5 and 
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CXCL10 in response to ATRi-RT. No differences were seen at this time point in interferon 
mRNA transcripts (data not shown).  
 
Many proteins can bind dsDNA triggering an immune response, forming an innate immune 
recognition system for dsDNA viruses. There has been significant recent interest in the 
ability of cGAS-STING to trigger inflammation through recognition of cytoplasmic host 
dsDNA (8, 18).  We checked mRNA transcript results for TLRs or potential intracellular 
dsDNA binding proteins which may share functional similarity to STING, as well as cGAS 
and STING/Tmem173 themselves.  
 
We observed an increase in cGAS by western blot in tumors treated with ATRi-RT, as well 
as an increase in the interferon-stimulated gene product IFIH1 (MDA-5) (Fig. 5D).  Analysis 
of gene expression data in the TC-1 tumors found statistically significant increases at the 
transcript level were present for Tlr1,6,7,8 and Tlr9, with the largest change in Tlr9 (Fig 5E).  
In keeping with a role for pattern recognition receptors, we also observed an increase in Irf7 
and 8 with combination therapy (Fig. 5F). increases in pattern recognition receptors for 
cytoplasmic nucleic acids (19): Ddx58/RIG-I, and Ifih1/MDA5, both RNA sensors and 
Zbp1/DAI (20) and Ddx60 (21), which sense DNA.  There was no change in STING 
(Tmem173) expression (Fig. 5G).  When we performed the analysis on separated immune 
and tumor cells, we found that treatment induced significant increases in transcript levels in 
the non-immune cells within the tumor (Fig. 5H). In all cases, as was observed for in vitro 
cytokine release, ATRi-RT led to the highest increase in transcript levels.   
 
CCL2, CCL5, CXCL10 and CXCL9 increases indicate that ATRi, RT and combination 
treatments induce pro-inflammatory responses.  There was disparity between the clear 
significance observed at the transcript level vs protein expression. This was attributed to the 
5-day post-treatment time point originally selected for gene expression analysis to favour 
assessment of infiltrating immune populations. Additionally, both transcript and protein 
assessment was not tumor-specific. To bring clarity on both these points, cytokine release 
from 2 human head and neck squamous cell carcinoma cell lines in vitro was measured in 
response to ATRi, radiation, or in combination at 72 h post treatment (Fig. 5I, J). We 
observed maximal increase in CXCL10 and CCL3 secretion with the combination treatment 
(Fig. 5I, J), CCL5 increased, but there was no significant detection of CCL2.  This suggests 
that part of the immune infiltration could be driven by tumor cell-intrinsic cytokine production. 
Almost without exception, radiation-induced cytokine and chemokine secretion from tumor 
cells was potentiated by the addition of ATRi. 
 








Radiotherapy is a standard of care in many tumor types. It is now well understood that 
radiotherapy can trigger immune responses and potentially lead to anti-tumor immunity (1). 
Despite advances in targeted delivery of radiotherapy, normal tissue toxicity imposes a limit 
upon further dose escalation. Small molecule radiosensitizers such as ATRi present a 
potential means to improve responses to radiotherapy by increasing tumor-selective cell kill. 
Through broad profiling of the immune landscape, we have demonstrated preclinical 
evidence that combination therapy with ATR inhibition can modulate the radiation-induced 
inflammatory tumor microenvironment. 
 
It has been recognised for some time that radiation has various effects on the tumor 
microenvironment, in particular the infiltrating immune compartment.  These effects can 
have positive and negative implications for tumor control (1).  Radiation is also known to 
enhance the infiltration of immune suppressive cells, such as Tregs, TAMs and MDSCs.  
These cells may increase the resistance of tumors to therapy and confer pro-malignant 
properties (4). Available preclinical data suggest there is no increased normal tissue toxicity 
from the combination of ATRi-RT (22, 23), but little is known about the effect of radiation 
sensitising drugs on the tumor microenvironment.  It is increasingly recognised that targeted 
therapies may have immunomodulatory effects.  For example, CDK4/6 inhibition has been 
shown to promote anti-tumor immunity, by increasing levels of intracellular double-stranded 
RNA, stimulating interferon production and antigen presentation, as well as by inhibiting Treg 
proliferation (24).  Treatment of tumor cell lines with PARP inhibitors causes upregulation of 
PD-L1, through a mechanism involving inactivation of GSK3/ (25). It is also recognised 
that modulation of anti-tumor immunity may enhance radiation responses by overcoming the 
radiation-induced upregulation of immunosuppressive factors.  For example, blocking the 
PD-L1 receptor overcomes radiation resistance, in a CD8-dependent manner (26). The 
picture that we have observed in this preclinical model is that ATRi in combination with 
radiation enhances infiltration of almost all immune populations. This appears to be a non-
selective amplification of radiation-induced effects. As such, this results in increased 
infiltration of therapeutically beneficial cells such as dendritic cells and CD8+ CTLs, but also 
enhancement of potentially suppressive populations. 
 
During the preparation of this manuscript, work by Vendetti and colleagues (27) 
demonstrated potentiation of radiation-induced cytotoxic T-cell activity when ATRi was 
added to 2 x 2 Gy radiation, as well as a reversal of the radiation-induced PD-L1 expression 
on tumor cells, a reduction in tumor-infiltrating Tregs and enhanced anti-tumor immunologic 
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memory in a mouse model of colorectal cancer.  Although no comment was made in that 
work about myeloid populations, the modulation of immune responses by ATRi-RT is 
notable, and highlights the differences in immune infiltrates and responses to therapy 
between tumour models, reflecting those seen in patients.  This may be due to the 
differences in immunogenicity of the tumor model used, as well as differences in the 
capacity to respond to intracytoplasmic nucleic acids the spectrum of cytokines released by 
the tumour cells in response to DNA damage.  We also note that the time point chosen for 
analysis may result in significant differences in the observed immune infiltrate, as noted by 
that work. 
 
Functional assays are required to determine if the cd11b+ Gr1+ cells are a truly 
immunosuppressive cell population, such as MDSCs. MDSCs suppress T-cell functions 
through depletion of arginine by arginases 1 and 2, and signalling to T-cells which results in 
dysfunction, proliferative arrest and induction of the Treg phenotype (28).  Monocytic MDSC 
can differentiate into tumor-associated macrophages and inflammatory DCs (29).  The 
functions of macrophages may be immunostimulatory (M1-like) or immunosuppressive (M2-
like), depending upon their subtype (30).  We have described ATRi amplification of radiation 
effects as indiscriminate, and this appears to extend to the vast majority of populations 
investigated. On preliminary analysis, there was no shift in macrophage polarity based on 
the M2 marker CD206, but further analyses would be required to determine the properties of 
the infiltrating macrophages.  Immunosuppressive DCs have also been described in tumors, 
expressing indoleamine 2, 3-dioxygenase 1 (IDO-1) which suppresses T-cell activity (31).  
No significant changes in Ido1 gene expression were observed in this experiment (but this 
was not verified on protein level (data not shown)). Little change in subtype proportion was 
observed for Ly6C and Ly6G subpopulations with CD11b+ Gr-1+ cells.  
 
We were interested in trying to identify the root cause behind the ability of ATRi to enhance 
radiation-induced immune cell infiltration. Interactions between the DDR and anti-tumor 
immunity are becoming better understood (6). We have previously shown that the 
mechanism of radiosensitization by AZD6738 involves mitotic catastrophe with the 
generation of acentric micronuclei (32).  Recent data have shown these micronuclei are 
subject to breakdown of the micronuclear envelope results in activation of cyclic GMP-AMP 
synthase (cGAS), which generates cyclic GMP-AMP (cGAMP), activating a type I interferon 
response via the STING (stimulator of interferon genes) pathway (18). Mitotic progression in 
the presence of micronuclei is required for their stimulation of immune responses (8). A 
previous study indicated that DDR-deficient breast tumors were defined by interferon 
signalling (7).  In that study CXCL10 and CCL5 were significantly upregulated in DNA repair 
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deficient cells in a cGAS/STING dependent manner with chemoattraction of PBMCs 
dependent on CXCL10 and CCL5. The similarity of radiation and ATRi (a pharmacologically 
induced DDR defect) in regards to CXCL10 and CCL5 expression was striking. 
 
These recent findings in the literature lead us to look at transcriptional levels of STING 
where no increase was observed. This does not preclude STING functional activity at a 
steady gene expression state.  Levels of cGAS and transcriptional levels of a number of 
other potential nucleic acid-sensing proteins were, however, upregulated coinciding with 
increased Irf7.  There was a significant increase in Z-DNA-binding protein 1 (Zbp1), in ATRi-
RT vs. control.  ZBP1 is a cytosolic DNA sensor which stimulates type-I interferon production 
and the production of CXCL10, signalling through IRF3 and IRF7 (20). Cytosolic DNA can 
also activate RIG-I (Ddx58) via DNA-dependent RNA polymerase III signalling (33).  RIG-I 
stimulation has been shown to cause CXCL10 and CCL5 release from tumor cells and 
upregulate HLA class I (34).  Another RNA sensor, interferon-induced helicase C domain-
containing protein-1 (Ifih1) also causes CXCL10 release upon stimulation (35). 
Rsad2/viperin was increased under all treatments and is an interferon-inducible gene 
promoting TLR9 signalling in pDC (15). This pathway detects viral and self-DNA, stimulating 
the transcription of type 1 interferon by signalling through IRF7.  We recognize that other 
pathways may also be involved in the inflammatory response to radiation, including absent 
in melanoma 2 (AIM2)(36), whether these are modulated by the addition of ATRi is currently 
not known. 
 
Due to the 5-day post-radiation timepoint, only indirect evidence of a type-I interferon 
response after ATRi-RT treatment was shown by the upregulation of multiple interferon-
stimulated genes (ISGs) in tumor cells (37).  The outlined nucleic acid sensors are known to 
be ISGs.  Hence, we cannot definitively state whether these genes are induced in response 
to cytosolic nucleic acids directly, or in response to type-I interferon production from a 
different source. It is unlikely that elevated levels of these proteins are not functionally active 
in some capacity in sensing cytoplasmic dsDNA in response to radiation and ATRi. Future 
work is needed to establish the exact functional relevance of these proteins.  
 
In vitro cell line experiments, and gene expression analysis of sorted immune and non-
immune cells, showed cytokines produced by proliferating tumor cells subjected to radiation 
and ATRi are likely to contribute significantly to the immune infiltration observed. In our 
model, tumor cells alone secreted CXCL10 and CCL5 with combination treatment.  CCL5 is 
chemotactic for macrophages and T-cells, and plays a role in activating NK cells (in 
conjunction with signals from activated T-cells). Hence, DNA damage may activate DNA-
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sensing pathways within the cell to cause release of CXCL10 and CCL5, attracting innate 
immune cells into the tumor which subsequently activate an adaptive response. CCL5 (i) is a 
target of NF-B activity, again released by multiple cell types including immune, stromal and 
tumor cells, (ii) recruits cells including T-cells and macrophages, and (iii) stimulates NK cell 
activation.  CCL5, along with CCL2, has also been implicated in cancer progression and 
metastasis, through multiple mechanisms, including the generation of MDSCs (38, 39) (40), 
and the attraction of inflammatory monocytes which subsequently differentiate into 
macrophages capable of promoting metastasis (41, 42). CCL2 is secreted by multiple cell 
types, including tumor cells and endothelial cells, with the major source being 
monocytes/macrophages (43)  Tumor-associated macrophages also produce CCL22 which 
attracts Tregs (31).  Ccl22 is one of the significantly upregulated genes with the ATRi-RT 
combination vs. control (Fig. 5A, B).  Overall, our data support the hypothesis that DNA 
damage within the tumour cells leads to an interferon response, and cytokine release 
leading to modulation of the immune microenvironment. The addition of ATRi boosts this 
radiation induced response. 
 
Publications in the literature have shown positive preclinical results for radiation in 
combination with anti-PD1 (44) and anti-CTLA4 (45) therapies. Our data point to a myeloid-
heavy infiltrate in response to ATRi-RT. This may offer an alternative immuno-oncology 
angle of attack where anti-PD1 or -CTLA4 fails. Translational research from the ongoing 
AZD6738 and radiation clinical trial (46) may also give further information about the 
immunogenicity of the combination. We have chosen to investigate the effects of ATRi on a 
clinically-relevant radiation dose schedule of 2 Gy per fraction, most commonly used in 
radical treatments, and the dose per fraction currently being assessed in the clinical study of 
AZD6738 with radiation (47).  We acknowledge that optimal dose-fractionations for immune 
stimulation are still under investigation, and are likely to be moderately large doses per 
fraction.  The effect of radiosensitizers on these dose-fractionations is the subject of ongoing 
study, but in the clinic, drug sensitisation of large fractions is avoided due to concerns 
regarding toxicity. In the radiation field, analysis of fractionation effects with radiosensitizing 
drugs to see whether they can be optimised not only for tumor kill, but potentially selection of 
a more favourable profile of immune infiltrates would be of great interest. 
 
In conclusion, we have shown an immunomodulatory effect of ATR inhibition with 
radiotherapy on the tumor microenvironment.  Radiosensitization by ATRi is well 
established, but to fully exploit the potential of G2/M cell cycle checkpoint-targeted agents in 
cancer treatment we need to understand the effect of these agents on immune responses. 
ATR inhibition can boost the immunogenic response to radiotherapy. Understanding the 
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suppressive immune populations in this context is critical to enhancing anti-tumor immunity 
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Figure 1: AZD678 therapeutic efficacy combined with fractionated radiotherapy in vivo 
corresponds to increased CD3+ and B220+ cell infiltration by IHC.  
A, Relative tumor growth curves for C57Bl/6 mice carrying subcutaneous TC1 tumors, 
treated with vehicle, AZD6738 75 mg/kg daily for 5 days, radiation 2 Gy x 4 (daily fractions), 
or AZD6738 with radiation; the first dose of AZD6738 was administered 2 h prior to 
irradiation and the last dose was administered the day after the final fraction of radiation. 
Asterisk represents p <0.05 between radiation and radiation + ATRi curves by unpaired t-
test. Minimum 10 animals per group.  B, quantification of TC1 tumors from (A) stained for 
CD3 by immunohistochemistry.  Minimum 10 fields of view and at least 3 tumors analysed 
per condition.  Average number per field is shown for each tumor, tumors were harvested 5 
days after the last fraction of radiation was administered. C, quantification of B220-positive 
cells, as per (B). 
 
Figure 2: Nanostring gene expression analysis reveals AZD6738 significantly modules 
radiation induced immune-linked transcripts in vivo.  
A, Overview of differential gene expression with ATR-radiation combinations in the TC-1 
murine model at 5 days after the end of 4 x 2 Gy radiation in the presence or absence of 
AZD6738. Differential expression analysis of NanoString data was performed, and gene 
functional annotations used to classify each gene with significantly altered expression into 
one of the above groups. Genes with significant change in expression (with p < 0.05 by 
Benjamini-Yekutieli Method) were grouped into functional categories and the number of 
genes with significant differential expression per category is shown for the indicated pairwise 
comparisons. Legend indicates which two groups were compared. 
B, Venn diagram illustrating numbers of genes with significant changes in expression for the 
indicated combinations.  C, Venn diagram illustrating interferon-stimulated genes, for ATRi-
RT combination treatment.  The number of genes stimulated by each of type I, II and III 
interferons is demonstrated.  Overall, there is a greater representation of genes that are 
stimulated by type I interferons in the database, and very few by type III interferons, so this 
may lead to a degree of bias in these results (from Interferome database). 
 
Figure 3: AZD6738 increases radiation induced lymphoid infiltration in vivo. 
A, number of lymphoid cells per mg tumor was calculated 5 days after the end of 4 x 2 Gy 
radiation in the presence or absence of AZD6738.  Error bars: SD (one direction only if lower 
SD outside the plotted area), asterisks: statistical significance by ANOVA with multiple 
comparisons, Min. 3 independent repeats of at least 3 animals per group. Populations were 
identified by the markers: CD3, CD3+; CD4eff, CD3+CD4+FOXP3-; Treg, 
CD3+CD4+FOXP3+; CD8, CD3+CD8+; NK, CD3-B220-NK1.1+; B cell, B220+. B, change in 
proportion of Granzyme B (GzB+) or Ki67+ CD8+ cells as a proportion of total CD8+ cells, 
and Ki67+ (proliferating) cells as a proportion of total CD4+FOXP3- or CD4+FOXP3+ cells. 
Error bars: SEM. C, mRNA transcript fold change in whole tumor lysates at 5 days after 
completion of radiotherapy. Copy number normalised to median controls. Mean and SD 
plotted, asterisks: statistical significance by ANOVA with multiple comparisons.  D, change in 
proportion of effector, regulatory and CD8-positive T cells, as a function of total CD3-positive 
cells, and Ki67-positive Treg, Teff and CD8 positive, as a proportion of total Treg, Teff and CD8-
positive cells, in draining lymph node (ipsilateral inguinal node), five days after completion of 
radiotherapy, min. 3 animals per group. E, normalised fluorescence intensity (normalised to 
mean of control fluorescence) of effector CD4 T-cells (CD3+, CD4+, FoxP3-), for the 
indicated markers of activation in tumor infiltrating cells in TC-1 tumors 5 days after the end 
of 4 x 2 Gy radiation in the presence or absence of AZD6738. Minimum 3 animals per group 
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in 2 independent experiments. F, fold-change mRNA transcript counts for corresponding 
genes indicating T cell activation, in a cell population sorted for CD45 in ATRi-RT treated 
tumours, relative to the median value for the control samples of each gene, mean and SD 
are plotted, asterisks: significance by unpaired t-test between ATRi-RT and control 
 
Figure 4, AZD6738 increases radiation induced myeloid infiltration in vivo.  
A, Assessment of tumor infiltrating myeloid cells at day 5 after treatment. Populations were 
identified as follows: B cells, B220+; dendritic cells, CD11c+ MHCII+; macrophages (Mac), 
CD11b+ CD11c- CD68+ SSCLow, MHC-2+, Gr-1Low-Int; CD11b+ Gr-1Int-Hi NK1.1- CD3-. 
Asterisks: statistical significance by ANOVA with multiple comparisons testing.  B, 
Proportions of CD206-positive and negative tumor-infiltrating macrophages, as a marker of 
M2a and M2c macrophages. C, proportions of CD11b+Gr-1+ subsets: proportions of 
CD11b+ Ly6CHigh for monocytic and Ly6CLow for granulocytic, no significant difference 
between control and ATRi+RT; D, Dendritic cells (CD11C+ MHC2+) were stained with B220, 
a marker of plasmacytoid DC. Proportion of parent shown. E, Flow cytometric analysis of 
PD-L1 staining for the indicated tumor subpopulations: CK+ indicates pan-cytokeratin 
positive cells, a surrogate for tumor cells. Mac = Macrophages (CD11b+, CD3-, NK1.1-, 
CD11cLow, CD68+, MHCII+, Gr1Low-int); Gr-1 = CD11b+, Gr1+, CD3- NK1.1-.  F, mRNA 
counts for PD-L1 (Cd274), expressed as fold change in ATRi-RT treated tumours compared 
with control, in tumour populations sorted by CD45 status. G, flow cytometric analysis of 
tumor cells (pan-cytokeratin positive), showing mean fluorescence intensity for MHC-1 
(mouse: H-2Kb). Mean fluorescence normalised to average control value. H, mRNA 
expression of genes involved in antigen processing and presentation, fold change in ATRi-
RT vs. control, expressed as fold change in ATRi-RT treated tumours compared with control, 
in tumour populations sorted by CD45 status.  All panels: 5 days after the end of treatment 
with 4 x 2 Gy radiation in the presence or absence of AZD6738. Minimum 3 tumors per 
condition, 2 independent experiments. significance: ANOVA with multiple comparisons 
(except F, H: unpaired t-test), mean and SD displayed.  
 
Figure 5, ATRi-RT causes modulation of cytokine production 
Analysis of changes in cytokine expression with ATR—radiation combinations, 5 days after 
treatment with 4 x 2 Gy radiation in the presence or absence of AZD6738. A, mRNA 
expression data, only statistically significant changes are displayed.  Mean of 3 replicates 
displayed. Fold change from control tumors displayed. Grey boxes: no significant difference 
found. B, Cytokine, chemokine, and receptor transcript analysis, as for (A), in tumour 
populations sorted by CD45-status.  Grey boxes: no transcripts. C, protein expression by 
cytokine array. Densitometry of array was measured and then normalised to positive and 
negative controls. Two tumors per group were analysed in duplicate. Mean of 2, Log2 fold 
change replicates displayed. D, western blot showing changes in the indicated proteins in in 
vivo samples after vehicle or ATRi+RT treatment, 5 days after the end of irradiation. E, 
mRNA expression of toll-like receptor (TLR) transcripts. F, mRNA expression of interferon 
regulatory factor (IRF) transcripts. G, mRNA expression of the indicated nucleic acid-sensing 
proteins. A-G: at 5 days after the final dose of radiotherapy, 3 animals per group, mean and 
S.D. displayed, analysed by ANOVA with multiple comparisons. H, Analysis of transcripts for 
nucleic acid sensors as for (G), on sorted populations of CD45-positive and –negative 
tumour cells. Asterisk: significance by unpaired t-test compared with control group for same 
cell population. I, J, measurement of cytokine concentration in supernatant of tumor cell 
lines FaDu (I) and HN5 (J) at 72 hours after treatment with DMSO, AZD6738 (0.5 µM), an 8 
Gy fraction of radiation, or radiation in combination with AZD6738 (added 1 hour prior to 
irradiation).  Supernatant was analysed by mutliplex bead-based flow cytometry.  Only 
analytes detected above lower limit of quantification are displayed.  Mean of two 
independent experiments, each run in duplicate, displayed. 
 
 





